Exicure (NASDAQ:XCUR – Get Free Report) issued its earnings results on Friday. The company reported ($0.39) earnings per share (EPS) for the quarter, Zacks reports.
Exicure Stock Down 6.8%
XCUR stock traded down $0.29 during trading on Friday, hitting $3.96. The company had a trading volume of 28,624 shares, compared to its average volume of 24,279. The firm has a 50-day moving average price of $4.42 and a 200-day moving average price of $7.00. The firm has a market cap of $25.02 million, a PE ratio of -1.02 and a beta of 3.74. Exicure has a 1-year low of $2.57 and a 1-year high of $36.00.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Exicure in a research note on Wednesday. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.
About Exicure
Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.
Featured Articles
- Five stocks we like better than Exicure
- Why Invest in 5G? How to Invest in 5G Stocks
- Qualcomm Earnings Surprise Wall Street—Here’s What Q4 Could Deliver
- 5 Top Rated Dividend Stocks to Consider
- MarketBeat Week in Review – 11/03 – 11/07
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- OpenAI’s Restructuring Sets up What Could Be the Biggest IPO Ever
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
